Leniolisib for Immune Dysregulation in CVID
A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)
Sponsor: Lahey Hospital & Medical Center
A PHASE2 clinical study on Common Variable Immunodeficiency (CVID), this trial is ongoing. The trial is conducted by Lahey Hospital & Medical Center and has accumulated 6 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Aug 2025 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
First recorded
Feb 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lahey Hospital & Medical Center
- Pharming Technologies B.V.
For direct contact, visit the study record on ClinicalTrials.gov .